Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.The Therapeutic Goods Administration (TGA) of Australia has awarded provisional approval for the use of Gilead Sciences’ remdesivir (Veklury) to treat Covid-19 patients, marking the first authorisation of treatment for this disease in the country.
The approval enables the use of the drug in adults and adolescents hospitalised with severe Covid-19 symptoms. TGA noted that, so far, remdesivir demonstrated the most promise as a treatment option to decrease hospitalisation time for people with coronavirus infections.